37 related articles for article (PubMed ID: 16760174)
1. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up.
Weide B; Eigentler TK; Pflugfelder A; Leiter U; Meier F; Bauer J; Schmidt D; Radny P; Pföhler C; Garbe C
Cancer Immunol Immunother; 2011 Apr; 60(4):487-93. PubMed ID: 21174093
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients.
Weide B; Eigentler T; Catania C; Ascierto PA; Cascinu S; Becker JC; Hauschild A; Romanini A; Danielli R; Dummer R; Trefzer U; Elia G; Neri D; Garbe C
Cancer Immunol Immunother; 2019 Sep; 68(9):1547-1559. PubMed ID: 31482307
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis.
Toor K; Middleton MR; Chan K; Amadi A; Moshyk A; Kotapati S
BMC Cancer; 2021 Jan; 21(1):3. PubMed ID: 33402121
[TBL] [Abstract][Full Text] [Related]
4. Determinants of combination GM-CSF immunotherapy and oncolytic virotherapy success identified through in silico treatment personalization.
Cassidy T; Craig M
PLoS Comput Biol; 2019 Nov; 15(11):e1007495. PubMed ID: 31774808
[TBL] [Abstract][Full Text] [Related]
5. Structure-based glycoengineering of interferon lambda 4 enhances its productivity and anti-viral potency.
Chung JH; Hong SH; Seo N; Kim TS; An HJ; Lee P; Shin EC; Kim HM
Cytokine; 2020 Jan; 125():154833. PubMed ID: 31479875
[TBL] [Abstract][Full Text] [Related]
6. Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia.
Forthun RB; Hellesøy M; Sulen A; Kopperud RK; Sjøholt G; Bruserud Ø; McCormack E; Gjertsen BT
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1729-1749. PubMed ID: 31111215
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Therapy of Uveal Melanoma: Current Status.
Triozzi PL; Singh AD
Ocul Oncol Pathol; 2014 Oct; 1(1):54-62. PubMed ID: 27175362
[TBL] [Abstract][Full Text] [Related]
8. Opposing effects of immunotherapy in melanoma using multisubtype interferon-alpha - can tumor immune escape after immunotherapy accelerate disease progression?
Strannegård Ö; Thorén FB
Oncoimmunology; 2016 Mar; 5(3):e1091147. PubMed ID: 27141351
[TBL] [Abstract][Full Text] [Related]
9. Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications.
Thorén FB; Anderson H; Strannegård Ö
Cancer Immunol Immunother; 2013 Oct; 62(10):1547-51. PubMed ID: 23979447
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant treatment of melanoma.
Moreno Nogueira JA; Valero Arbizu M; Pérez Temprano R
ISRN Dermatol; 2013; 2013():545631. PubMed ID: 23476798
[TBL] [Abstract][Full Text] [Related]
11. The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon.
Triozzi PL; Achberger S; Aldrich W; Singh AD; Grane R; Borden EC
J Transl Med; 2012 Dec; 10():241. PubMed ID: 23217102
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for melanoma: current status and perspectives.
Alexandrescu DT; Ichim TE; Riordan NH; Marincola FM; Di Nardo A; Kabigting FD; Dasanu CA
J Immunother; 2010; 33(6):570-90. PubMed ID: 20551839
[TBL] [Abstract][Full Text] [Related]
13. [Adjuvant therapy of melanoma. From non-specific immune stimulants into the future].
Hauschild A; Kleeberg UR
Hautarzt; 2006 Sep; 57(9):764-72. PubMed ID: 16927109
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial.
Stadler R; Luger T; Bieber T; Köhler U; Linse R; Technau K; Schubert R; Schroth K; Vakilzadeh F; Volkenandt M; Gollnick H; Von Eick H; Thoren F; Strannegård O
Acta Oncol; 2006; 45(4):389-99. PubMed ID: 16760174
[TBL] [Abstract][Full Text] [Related]
15. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
Kretschmer L; Helmbold P; Emmert S; Marsch WC
Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
[TBL] [Abstract][Full Text] [Related]
16. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
Rudolf Z; Strojan P
Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
[TBL] [Abstract][Full Text] [Related]
17. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
Lewis KD; Robinson WA; McCarter M; Pearlman N; O'Day SJ; Anderson C; Amatruda TT; Baron A; Zeng C; Becker M; Dollarhide S; Matijevich K; Gonzalez R
J Clin Oncol; 2006 Jul; 24(19):3157-63. PubMed ID: 16809738
[TBL] [Abstract][Full Text] [Related]
18. [Interferon: therapy in patients with cutaneous malignant melanoma in adjuvant setting].
Wcisło G; Szczylik C
Pol Merkur Lekarski; 2003 Jul; 15(85):5-8. PubMed ID: 14593950
[TBL] [Abstract][Full Text] [Related]
19. Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?
Bedikian AY; Johnson MM; Warneke CL; Papadopoulos NE; Kim KB; Hwu WJ; McIntyre S; Rohlfs M; Homsi J; Hwu P
Melanoma Res; 2011 Feb; 21(1):84-90. PubMed ID: 21102360
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
